Radioligand therapy targeting prostate specific membrane antigen (PSMA-RLT) is becoming increasingly important in palliative care of metastasized castration resistant prostate cancer (mCRPC) as a highly effective and low toxicity therapy option. In addition to its overexpression in prostate cancer cells, PSMA is also physiologically expressed in the kidneys which is raising concerns over dose related nephrotoxicity of PSMA-RLT. We describe potential positive short-term effects of PSMA-RLT on renal function with marked recovery of a pretreatment compromised kidney.
From the *Department of Nuclear Medicine, Saarland University Hospital, Homburg, Germany
†Department of Oncology, Centre Hospitalier de Luxembourg, Luxembourg.
Received for publication January 22, 2019; revision accepted May 26, 2019.
Conflicts of interest and sources of funding: none declared.
Consent to publish: Informed consent was obtained from the individual participant included in the study.
Availability of data and materials: PET/CT and scintigraphy datasets are available from the corresponding author on request.
Correspondence to: Martin Ries, MD, Klinik für Nuklearmedizin, Uniklinikum des Saarlandes, Kirrberger Str., Homburg D-66421, Germany. E-mail: firstname.lastname@example.org.
Online date: July 8, 2019